Skip to main content
PMC home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;31(7):436–445. [Article in Spanish] doi: 10.1016/S0212-6567(03)79204-X

Síndrome metabólico, resistencia a la insulina y diabetes. ¿Qué se oculta bajo la punta del iceberg?

B Costa a,b,*, JJ Cabré a, F Martín a
PMCID: PMC7679766  PMID: 12735887

The content is available as a PDF (372.8 KB).

Bibliografía

  • 1.Lebovitz H.E. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S135–148. doi: 10.1055/s-2001-18576. [DOI] [PubMed] [Google Scholar]
  • 2.Reaven G.M. Role of insulin resistance in human disease. Diabetes. 1988;37:1597–1607. doi: 10.2337/diab.37.12.1595. [DOI] [PubMed] [Google Scholar]
  • 3.Ferrannini E. Insulin resistance is central to the burden of diabetes. Diabetes Metab Rev. 1997;13:81–86. doi: 10.1002/(sici)1099-0895(199706)13:2<81::aid-dmr184>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  • 4.Keen H., Jarret R.J., McCartney P. The ten-year follow up of the Bedford survey (1962–1972); glucose tolerance and diabetes. Diabetologia. 1982;22:73–78. doi: 10.1007/BF00254832. [DOI] [PubMed] [Google Scholar]
  • 5.Ferrannini E., Haffner S.M., Mitchell B.D., Stern M.P. Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416–422. doi: 10.1007/BF00403180. [DOI] [PubMed] [Google Scholar]
  • 6.Hunter S.J., Garvey T. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction and glucose transport effector system. Am J Med. 1998;5:331–346. doi: 10.1016/s0002-9343(98)00300-3. [DOI] [PubMed] [Google Scholar]
  • 7.Baumgartner-Parzer S.M., Wallhausl W.E. The endothelium as a metabolic and endocrine organ: its relation with insulin resistance. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S166–179. doi: 10.1055/s-2001-18579. [DOI] [PubMed] [Google Scholar]
  • 8.Book C.B., Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84:3110–3116. doi: 10.1210/jcem.84.9.6010. [DOI] [PubMed] [Google Scholar]
  • 9.Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med. 1999;131:7–13. doi: 10.7326/0003-4819-131-1-199907060-00003. [DOI] [PubMed] [Google Scholar]
  • 10.Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850. doi: 10.2337/diabetes.50.8.1844. [DOI] [PubMed] [Google Scholar]
  • 11.Solomon C.G., Seely E.W. Brief review: hyper-tension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension. 2001;37:232–239. doi: 10.1161/01.hyp.37.2.232. [DOI] [PubMed] [Google Scholar]
  • 12.Hammarsten J., Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–158. doi: 10.1159/000052430. [DOI] [PubMed] [Google Scholar]
  • 13.Liao D., Sloan R.P., Cascio W.E., Folsom A.R., Liese A.D., Evans G.W. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care. 1998;21:2116–2122. doi: 10.2337/diacare.21.12.2116. [DOI] [PubMed] [Google Scholar]
  • 14.Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA. 1998;279:1477–1482. doi: 10.1001/jama.279.18.1477. [DOI] [PubMed] [Google Scholar]
  • 15.Festa A., D’Agostino R., Jr, Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS) Circulation. 2000;102:42–47. doi: 10.1161/01.cir.102.1.42. [DOI] [PubMed] [Google Scholar]
  • 16.Piatti P.M., Monti L.D., Galli L., Fragasso G., Valsecchi G., Conti M. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism. 2000;49:748–752. doi: 10.1053/meta.2000.6257. [DOI] [PubMed] [Google Scholar]
  • 17.Festa A., D’Agostino R., Jr, Mykkanen L., Tracy R., Howard B.V., Haffner S.M. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 leveles. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 1999;19:605–610. doi: 10.1161/01.atv.19.3.605. [DOI] [PubMed] [Google Scholar]
  • 18.Rainwater D.L. Lipoprotein correlates of LDL particle size. Atherosclerosis. 2000;148:151–158. doi: 10.1016/s0021-9150(99)00216-6. [DOI] [PubMed] [Google Scholar]
  • 19.Godsland I.F., Rosankiewicz J.R., Proudler A.J., Johnston D.G. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab. 2001;86:719–723. doi: 10.1210/jcem.86.2.7213. [DOI] [PubMed] [Google Scholar]
  • 20.Murata H., Hruz P.W., Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251–20254. doi: 10.1074/jbc.C000228200. [DOI] [PubMed] [Google Scholar]
  • 21.Mather K.J., Hunt A.E., Steinberg H.O., Paradisi G., Hook G., Katz A. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457–5464. doi: 10.1210/jcem.86.11.7880. [DOI] [PubMed] [Google Scholar]
  • 22.McAuley K.A., Williams S.M., Mann J.I., Walker R.J., Lewis-Barned N.J., Temple L.A. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460–464. doi: 10.2337/diacare.24.3.460. [DOI] [PubMed] [Google Scholar]
  • 23.Alberti K.G., Zimmet PZ for the WHO Consultation Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  • 24.Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
  • 25.SEEDO (Sociedad Española para el Estudio de la Obesidad) Consenso SEEDO’2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 2000;115:587–597. [PubMed] [Google Scholar]
  • 26.Matsumoto K., Sakamaki H., Izumino K., Yano M., Ueki Y., Miyake S. Increased insulin sensitivity and decreased insulin secretion in offspring of insulin-sensitive type 2 diabetic patients. Metabolism. 2000;49:1219–1223. doi: 10.1053/meta.2000.8623. [DOI] [PubMed] [Google Scholar]
  • 27.Taniguchi A., Fukushima M., Sakai M., Kataoka K., Nagata I., Doi K. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Metabolism. 2000;49:1001–1005. doi: 10.1053/meta.2000.7735. [DOI] [PubMed] [Google Scholar]
  • 28.Reaven G.M. Insulin resistance-how important is it to treat? Exp Clin Endocrinol Diabetes. 2000;108(Suppl 2):S274–S280. [Google Scholar]
  • 29.Weyer C., Hanson R.L., Tataranni P.A., Bogardus C., Pratley R.E. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes. 2000;49:2094–2101. doi: 10.2337/diabetes.49.12.2094. [DOI] [PubMed] [Google Scholar]
  • 30.Holness M.J., Langdown M.L., Sugden M.C. Early-life programming of susceptibility to dysregulation of glucose metabolism and the development of Type 2 diabetes mellitus. Biochem J. 2000;349:657–665. doi: 10.1042/bj3490657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Neel J.V. Diabetes mellitus: a «thrifty» genotipe rendered detrimental by «progress»? Am J Hum Genet. 1962;14:353–362. [PMC free article] [PubMed] [Google Scholar]
  • 32.Uchino H., Niwa M., Shimizu T., Nishiyama K., Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocrin J. 2000;47:639–641. doi: 10.1507/endocrj.47.639. [DOI] [PubMed] [Google Scholar]
  • 33.Groop L., Orho-Melander M. The dysmetabolic syndrome. J Intern Med. 2001;250:105–120. doi: 10.1046/j.1365-2796.2001.00864.x. [DOI] [PubMed] [Google Scholar]
  • 34.Steppan C.M., Balley S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312. doi: 10.1038/35053000. [DOI] [PubMed] [Google Scholar]
  • 35.Targher G., Bonadonna R.C., Alberiche M., Zenere M.B., Muggeo M., Bonora E. Relation between soluble adhesion molecules and insulin sensitivity in type 2 diabetic individuals: role of adipose tissue. Diabetes Care. 2001;24:1961–1966. doi: 10.2337/diacare.24.11.1961. [DOI] [PubMed] [Google Scholar]
  • 36.Fujimoto W.Y., Bergstrom R.W., Boyko E.J., Chen K.W., Kahn S.E., Leonetti D.L. Preventing diabetes applying pathophysiological and epidemiological evidence. Br J Nutr. 2000;84(Suppl 2):S173–176. doi: 10.1079/096582197388635. [DOI] [PubMed] [Google Scholar]
  • 37.Ryan A.S. Insulin resistance with aging: effects of diet and exercise. Sports Med. 2000;30:327–346. doi: 10.2165/00007256-200030050-00002. [DOI] [PubMed] [Google Scholar]
  • 38.Fernández-Real J.M., Vayreda M., Casamitjana R., Saez M., Ricart W. Índice de masa corporal (IMC) y porcentaje de masa grasa: un IMC mayor de 27,5 kg/m2 podría suponer obesidad en la población española. Med Clin (Barc) 2001;117:681–684. [PubMed] [Google Scholar]
  • 39.Golub M.S. The adrenal and the metabolic syndrome. Curr Hypertens Rep. 2001;3:117–120. doi: 10.1007/s11906-001-0022-x. [DOI] [PubMed] [Google Scholar]
  • 40.Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689. doi: 10.2337/diacare.24.4.683. [DOI] [PubMed] [Google Scholar]
  • 41.Maiques Galán A. ¿Qué riesgo coronario presentan nuestros pacientes diabéticos? Aten Primaria. 2002;29:205–212. [Google Scholar]
  • 42.Gerstein H.C., Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet. 1996;347:949–950. doi: 10.1016/s0140-6736(96)91420-8. [DOI] [PubMed] [Google Scholar]
  • 43.Harding A.H., Williams D.E., Hennings S.H., Mitchell J., Wareham N.J. Is the association between dietary fat intake and insulin resistance modified by physical activity? Metabolism. 2001;50:1186–1192. doi: 10.1053/meta.2001.26702. [DOI] [PubMed] [Google Scholar]
  • 44.McAuley K.A., Williams S.M., Mann J.I., Goulding A., Chisholm A., Wilson N. Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes Care. 2002;25:445–452. doi: 10.2337/diacare.25.3.445. [DOI] [PubMed] [Google Scholar]
  • 45.Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X. Effect of diet and exercice in preventing NIDDM in people with impaired glucose tolerance: The Da Quing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544. doi: 10.2337/diacare.20.4.537. [DOI] [PubMed] [Google Scholar]
  • 46.Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350. doi: 10.1056/NEJM200105033441801. [DOI] [PubMed] [Google Scholar]
  • 47.Costa B., Piñol J.L., Donado A., Martín F., Castell C., Grupo de Investigación ITG (Reus-Tarragona) Incidencia significativa de la diabetes tipo 2 en la población española de alto riesgo. Resultados del estudio ITG(2) Med Clin (Barc) 2002;118:287–293. doi: 10.1016/s0025-7753(02)72362-2. [DOI] [PubMed] [Google Scholar]
  • 48.Polonsky K.S., Given B.D., Hirsch L.J., Tillil H., Shapiro E.T., Beebe C. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;12(318):1231–1239. doi: 10.1056/NEJM198805123181903. [DOI] [PubMed] [Google Scholar]
  • 49.Schoonjans K., Auwers J. Thiazolidinediones: an update. Lancet. 2000;355:1008–1010. doi: 10.1016/S0140-6736(00)90002-3. [DOI] [PubMed] [Google Scholar]
  • 50.Sunayama S., Watanabe Y., Daida H., Yamaguchi H. Thiazolidinediones, dyslipidaemia and insulin resístance syndrome. Curr Opin Lipidol. 2000;11:397–402. doi: 10.1097/00041433-200008000-00009. [DOI] [PubMed] [Google Scholar]
  • 51.Goldstein B.J. Rosiglitazone. Int J Clin Pract. 2000;54:333–337. [PubMed] [Google Scholar]
  • 52.Uehara M.H., Kohlmann N.E., Zanella M.T., Ferreira S.R. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2001;3:319–325. doi: 10.1046/j.1463-1326.2001.00136.x. [DOI] [PubMed] [Google Scholar]
  • 53.Marchesini G., Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology. 2002;35:497–499. doi: 10.1053/jhep.2002.31551. [DOI] [PubMed] [Google Scholar]
  • 54.Heymsfield S.B., Segal K.R., Haupman J. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321–1326. doi: 10.1001/archinte.160.9.1321. [DOI] [PubMed] [Google Scholar]
  • 55.Yusuf S., Gerstein H., Hoogwerf B., the HOPE Study Investigators Ramipril and the development of diabetes. JAMA. 2001;286:1882–1885. doi: 10.1001/jama.286.15.1882. [DOI] [PubMed] [Google Scholar]
  • 56.Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:346–347. doi: 10.1161/01.cir.103.3.357. [DOI] [PubMed] [Google Scholar]
  • 57.Van Zwieten P.A. Centrally acting antihypertensive drugs. Present and future. Clin Exp Hypertens. 1999;21:859–873. doi: 10.3109/10641969909061015. [DOI] [PubMed] [Google Scholar]
  • 58.Kraegen E.W., Cooney G.J., Ye J.M., Thompson A.L., Furler S.M. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type 2 diabetes and obesity. Exp Clin Endocrinol Diabestes. 2001;109(Suppl 2):S189–201. doi: 10.1055/s-2001-18581. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES